Immunic, Inc. (10VA.F)

1,2460 -0,0430 (-3,34%) Ab 08:02AM CEST. Markt geöffnet.

Immunic, Inc.

1200 Avenue of the Americas
Suite 200
New York, NY 10036
United States
332 255 9818
https://imux.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 77

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Duane D. Nash J.D., M.B.A., M.D.	Executive Chairman	469,04k	N/A	1971
Dr. Daniel Vitt Ph.D.	CEO, President & Director	808,7k	N/A	1968
Mr. Glenn Whaley CPA	Chief Financial Officer	536,23k	N/A	1968
Dr. Andreas Muehler M.D., Ph.D.	Chief Medical Officer	645,93k	N/A	1965
Dr. Hella Kohlhof	Chief Scientific Officer	N/A	N/A	1974
Jessica Breu	Head of Investor Relations & Communications	N/A	N/A	N/A
Mr. Inderpal Singh	General Counsel	N/A	N/A	1967
Mr. Patrick Walsh	Chief Business Officer	N/A	N/A	1984

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Corporate Governance

Immunic, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 8, Vorstand: 9, Shareholderrechte: 6, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.